Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Integrated incremental immunoreactive insulin and connecting peptide responses to an oral glucose load of 50 g and an "isoglycaemic" intravenous glucose infusion, respectively, were measured in 14 Type 2 (non-insulin-dependent) diabetic patients and 8 age- and weight-matched metabolically healthy control subjects. Differences between responses to oral and intravenous glucose administration are attributed to factors other than glucose itself (incretin effect). Despite higher glucose increases, immunoreactive insulin and connecting peptide responses after oral glucose were delayed in diabetic patients. Integrated responses were not significantly different between both groups. However, during "isoglycaemic" intravenous infusion, insulin and connecting peptide responses were greater in diabetic patients than in control subjects as a consequence of the higher glycaemic stimulus. The contribution of incretin factors to total insulin responses was 72.8 +/- 6.9% (100% = response to oral load) in control subjects and 36.0 +/- 8.8% in diabetic patients (p less than or equal to 0.05). The contribution to connecting peptide responses was 58.4 +/- 7.6% in control subjects and 7.6 +/- 14.5% (p less than or equal to 0.05) in diabetic patients. Ratios of integrated insulin to connecting peptide responses suggest a reduced (hepatic) insulin extraction in control subjects after oral as compared to intravenous glucose. This was not the case in diabetic patients. Immunoreactive gastric inhibitory polypeptide responses were not different between control subjects and diabetic patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“People with obesity and/or T2D have impaired incretin release ( Toft-Nielsen et al., 2001 ; Vilsbøll et al., 2001 ) and/or function ( Nauck et al., 1986 ; Muscelli et al., 2008 )”
From Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes (2024) · cites this paper as Nauck et al., 1986
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 2×
“Thus the study of Perley and Kipnis [ 10 ] from 1967 does not - in the absence of C-peptide measurements - allow final conclusions about the incretin effect in Type 2 diabetic patients.”
BackgroundSeltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 883
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 5×
“In healthy young subjects, a clear dose-dependency of incretin effects after oral glucose has been observed [6].”
BackgroundResultInfluentialSelf-citationRadioimmunological determination of human C-peptide in serum
Heding, L. G. (1975) · Diabetologia · doi:10.1007/bf01222104 · Cited by 830
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2].”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Arguing against this explanation, intravenous isoproterenol [36] or glucagon [ 37 ] enhanced, rather than diminished, additional B cell secretory responses in Type 2 diabetic patients when plasma glucose levels had been elevated by glucose infusion up to the range employed in our study.”
ResultC-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
Polonsky, K. S., & Rubenstein, A. H. (1984) · Diabetes · doi:10.2337/diab.33.5.486 · Cited by 476 · cited 3×
“This conclusion must, however, remain speculative because of reservations regarding the "insulin to C-peptide ratio method" for estimating changes in (hepatic) insulin extraction [ 33 ].”
BackgroundMethodInfluentialTHE PLASMA INSULIN RESPONSE TO GLUCOSE INFUSION IN HEALTHY SUBJECTS AND IN DIABETES MELLITUS
Cerasi, E., & Luft, R. (1967) · Acta Endocrinologica · doi:10.1530/acta.0.0550278 · Cited by 371 · cited 2×
“The markedly reduced incretin effect found in our group with a more severe degree of Type 2 diabetes may simply be an expression of their impaired capacity to secrete insulin at an adequate rate [3, 4 ]. The glycaemic stimulus with plasma glucose values of -17mmol/1 (300mg/dl) may already have led to maximal B cell st…”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Insulin secretion after an oral glucose load is due to stimulation of the pancreatic B cell by elevation of the plasma glucose level and, in addition, by incretin factors (gastrointestinal hormones and possibly nerves) which potentiate the secretory response to hyperglycaemia alone [1, 2 ].”
Background
Research works printed but not linked: 4
- Bloom SR (1975) GIP in diabetes (abstract). Diabetologia 11: 334
- WHO Expert Committee on Diabetes Mellitus, Second Report, Technical Report Series 646, WHO, Geneva, 1980
- Madison LL, Kaplan N (1958) The hepatic binding of I-131 labeled insulin in human subjects during a single transhepatic circulation. J Lab Clin Med 52: 927–932
- Ross SA, Brown JC, Dupre J (1974) Effects of Gastric Inhibitory Polypeptide on endocrine pancreas in normal and diabetic subjects. Diabetologia 10: 384 (Abstract)
Cited by
Items 101–200 of 1,001
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 181
Ryskjær, J., Deacon, C. F., Carr, R. D., Krarup, T., Madsbad, S., Holst, J., & Vilsbøll, T. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02221 · Cited by 181
“In 1986, Nauck et al. showed that type-2 diabetic patients have a markedly impaired incretin effect, which may contribute to the relative insulin deficiency seen in these patients ( 10 ).”
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
Gautier, J.-F., Choukem, S.-P., & Girard, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73397-4 · Cited by 183
“In these patients, circulating levels of GIP are normal [46,47] or increased [49] in basal and postprandial conditions.”
Power, O., Nongonierma, A. B., Jakeman, P., & FitzGerald, R. J. (2014) · Proceedings of the Nutrition Society · doi:10.1017/s0029665113003601 · Cited by 180
“However, in T2DM the incretin response is diminished and equates to approximately 50% of the response achieved in a healthy adult((17)).”
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Iqbal, J., Wu, H., Hu, N., Zhou, Y., Li, L., Xiao, F., Wang, T., Jiang, H., Xu, S., Huang, B., et al. (2022) · Obesity Reviews · doi:10.1111/obr.13435 · Cited by 179
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
Nauck, M. A., & Meier, J. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.014 · Cited by 180
Self-citationKendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.015 · Cited by 176
“Impaired insulin secretion [1,48,49] and β-cell dysfunction, [50] insulin resistance, obesity, and an impaired incretin effect [30] all play a role in the pathogenesis andprogression of type 2 diabetes (Figure 2).”
BackgroundTolhurst, G., Zheng, Y., Parker, H. E., Habib, A. M., Reimann, F., & Gribble, F. M. (2011) · Endocrinology · doi:10.1210/en.2010-0956 · Cited by 180
“but which is impaired in type 2 diabetes (3).”
Gut hormones and diabetes mellitus
Creutzfeldt, W., & Nauck, M. (1992) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610080206 · Cited by 176
Self-citationChapter 15 Glucose‐Dependent Insulinotropic Polypeptide (Gastric Inhibitory Polypeptide; GIP)
McIntosh, C. H. S., Widenmaier, S., & Kim, S. (2009) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)00615-8 · Cited by 171
Unraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
“Glucose triggers a much greater insulin-secretory response when ingested orally than when administered intravenously (IV) [30].”
BackgroundSelf-citationPharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Golightly, L. K., Drayna, C. C., & McDermott, M. T. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261927 · Cited by 158
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care · doi:10.2337/dc13-0465 · Cited by 158
Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 155
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Effects of Bariatric Surgery on Glucose Homeostasis and Type 2 Diabetes
Bradley, D., Magkos, F., & Klein, S. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.114 · Cited by 152
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Neumiller, J. J., Wood, L., & Campbell, R. K. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.5.463 · Cited by 150
“The incretin effect has been demonstrated to be impaired in people with type 2 diabetes, which may contribute to the inability of these patients to secrete an adequate amount of insulin to meet physiologic needs.(19) The etiology of this deficient incretin response is not entirely understood.”
BackgroundThe Liver–α-Cell Axis and Type 2 Diabetes
Wewer Albrechtsen, N. J., Pedersen, J., Galsgaard, K. D., Winther-Sørensen, M., Suppli, M. P., Janah, L., Gromada, J., Vilstrup, H., Knop, F. K., & Holst, J. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00251 · Cited by 149
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 147
“(59) of the loss of incretin effects in type 2 diabetes].”
BackgroundTseng, C. C., Kieffer, T. J., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119060 · Cited by 151
Laakso, M., Zilinskaite, J., Hansen, T. F., Boesgaard, T. W., Vänttinen, M., Stančáková, A., Jansson, P., Pellmé, F., Holst, J. J., Kuulasmaa, T., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0899-2 · Cited by 158
“Reduced incretin effect and reduced GLP-1 levels following a meal have previously been reported in type 2 diabetic participants as well as in those with IGT [29, 30], although the significance of this for the dysmetabolic state is unclear.”
BackgroundNeumiller, J. J. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.09078 · Cited by 161
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143
“[8] demonstrated that the incretin effect is impaired in patients with T2D.”
BackgroundGlucagon-like peptide-1: a major regulator of pancreatic beta-cell function
Perfetti, R., & Merkel, P. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1430717 · Cited by 143
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 158
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
“Albiglutide (formerly known as albugon) is a long-acting GLP-1R agonist, developed by GlaxoSmithKline through the genetic fusion of two repeats of human GLP-1(7-36) molecules to recombinant human albumin.”
BackgroundInfluentialGlucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M., Karagiannis, A., & Mikhailidis, D. P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 141
“The incretin effect seems to be significantly impaired in T2DM due to a reduced secretion of these hormones, accelerated metabolism or defective responsiveness to their action [4].”
BackgroundNutritional modulation of endogenous glucagon-like peptide-1 secretion: a review
Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139
“GLP-1 seems to be responsible for nearly half of the total postprandial insulin secretion [29].”
BackgroundThe Enteroinsular Axis and the Recovery from Type 2 Diabetes after Bariatric Surgery
Patriti, A., Facchiano, E., Sanna, A., Gullà, N., & Donini, A. (2004) · Obesity Surgery · doi:10.1381/0960892041590818 · Cited by 149
Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137
Self-citationBansal, M. B., Patton, H. M., Morgan, T. R. M., Carr, R. M., Dranoff, J. A., & Allen, A. M. (2025) · Hepatology · doi:10.1097/hep.0000000000001608 · Cited by 197
The Role of Incretins on Insulin Function and Glucose Homeostasis
Holst, J. J., Gasbjerg, L. S., & Rosenkilde, M. M. (2021) · Endocrinology · doi:10.1210/endocr/bqab065 · Cited by 124
“So, how important is the incretin effect in people? This is really an important question, because one of the characteristics of type 2 diabetes is a more or less complete loss of the incretin effect (13).”
BackgroundInfluentialBrunton, S. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12361 · Cited by 130
Piteau, S., Olver, A., Kim, S.-J., Winter, K., Pospisilik, J. A., Lynn, F., Manhart, S., Demuth, H.-U., Speck, M., Pederson, R. A., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.115 · Cited by 130
Overview of Newer Agents: Where Treatment Is Going
DeFronzo, R. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.008 · Cited by 161
How functional foods play critical roles in human health
Pang, G., Xie, J., Chen, Q., & Zhi-he, H. (2012) · Food Science and Human Wellness · doi:10.1016/j.fshw.2012.10.001 · Cited by 150
Gut peptides and type 2 diabetes mellitus treatment
Åhrén, B. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0079-9 · Cited by 135
Physiology of Incretins in Health and Disease
Deacon, C. F., & Ahrén, B. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.293 · Cited by 126
“In patients with type 2 diabetes, the incretin effect is clearly reduced [109, 110], which results in an inappropriately low insulin response to the 25-g-OGTT”
BackgroundMadsbad, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.008 · Cited by 134
Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
“Moreover, type 2 (non-insulin-dependent) diabetic patients exhibit a reduced incretin effect (Nauck et al., 1986).”
BackgroundPamir, N., Lynn, F. C., Buchan, A. M. J., Ehses, J., Hinke, S. A., Pospisilik, J. A., Miyawaki, K., Yamada, Y., Seino, Y., McIntosh, C. H. S., et al. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00270.2002 · Cited by 126
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“This name stems from the initial prediction from the complementary DNA sequence that GLP-1 would correspond to PG 72–108; however, the natural extractable peptide had a sequence corresponding to PG 78–107amide, truncated by six amino acids.”
InfluentialFisman, E. Z., & Tenenbaum, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01412-5 · Cited by 124
“It has been shown that in patients with type 2 diabetes mellitus (T2DM) the response to the incretin effect is altered as a result of a severe defect in the sensitivity for GIP in the β cells [4] and a reduction in food-induced GLP-1 secretion [5, 6].”
BackgroundEffect of endogenous GLP-1 on insulin secretion in type 2 diabetes
Salehi, M., Aulinger, B., Prigeon, R. L., & D'Alessio, D. A. (2010) · Diabetes · doi:10.2337/db09-1253 · Cited by 124
“Using this method Nauck and colleagues demonstrated a severe impairment of the incretin effect in subjects with type 2 diabetes (29), a much cited finding that has been very influential in shaping the understanding of enteroinsular physiology.”
InfluentialDeacon, C. F., & Holst, J. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.824966 · Cited by 122
“In T2D, the incretin effect is severely impaired [5], but exogenously administered GLP-1 still retains both its insulinotropic and glucagonostatic effects, and results in improvements in glycaemia [6].”
BackgroundLoss of Cyp8b1 Improves Glucose Homeostasis by Increasing GLP-1
Kaur, A., Patankar, J. V., de Haan, W., Ruddle, P., Wijesekara, N., Groen, A. K., Verchere, C. B., Singaraja, R. R., & Hayden, M. R. (2015) · Diabetes · doi:10.2337/db14-0716 · Cited by 126
“In contrast to insulin secretion induced by the intraperitoneal injection of glucose, increased insulin secretion after an oral glucose load is partly due to the action of incretins, an effect that is diminished in type 2 diabetes (22).”
BackgroundMethodIncretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
Boer, G. A., & Holst, J. J. (2020) · Biology · doi:10.3390/biology9120473 · Cited by 155
“In 1986 it was demonstrated that the incretin effect is severely reduced or even absent in patients with type 2 diabetes (T2DM) [5], even in patients with a considerable insulin secretory capacity, and the incretin deficiency is therefore one of the most important pathogenetic factors behind the impaired glucose toler…”
BackgroundO’Donovan, D. G., Doran, S., Feinle-Bisset, C., Jones, K. L., Meyer, J. H., Wishart, J. M., Morris, H. A., & Horowitz, M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0334 · Cited by 122
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
Self-citationPhillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 119
Cyclic AMP dynamics in the pancreatic β-cell
Tengholm, A. (2012) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.724732 · Cited by 144
“However, several aberrations in diabetic subjects may be envisaged to affect b-cell cAMP handling, such as the reduced incretin effect and alterations of glucagon secretion (159,160).”
Incretin effect: GLP-1, GIP, DPP4
Kazakos, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70011-0 · Cited by 153
Holst, J. J., & Deacon, C. F. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.005 · Cited by 131
Greenbaum, C. J., Prigeon, R. L., & D’Alessio, D. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.951 · Cited by 119
Montanya, E., & Sesti, G. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.11.034 · Cited by 127
BOSE, M., TEIXEIRA, J., OLIVAN, B., BAWA, B., ARIAS, S., MACHINENI, S., PI‐SUNYER, F. X., SCHERER, P. E., & LAFERRÈRE, B. (2010) · Journal of Diabetes · doi:10.1111/j.1753-0407.2009.00064.x · Cited by 119
“The incretin effect on insulin secretion is impaired in diabetes.(4) We have shown that both incretin levels and effects on insulin secretion are markedly increased 1 month after GBP in patients with diabetes,(2) but not after a matched weight loss by diet.”
BackgroundMethodRapid improvement in diabetes after gastric bypass surgery
Lingvay, I., Guth, E., Islam, A., & Livingston, E. (2013) · Diabetes Care · doi:10.2337/dc12-2316 · Cited by 116
“Both these studies were further limited by examining glucose dynamics in patients without diabetes who might not have the same defect in incretin physiology that is hypothesized to occur in obese patients with diabetes (19,20) whose diabetes improves after RYGB (21).”
BackgroundAaboe, K., Knop, F. K., Vilsbøll, T., Deacon, C. F., Holst, J. J., Madsbad, S., & Krarup, T. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01167.x · Cited by 112
DPP-4 inhibitors in the treatment of type 2 diabetes
Duez, H., Cariou, B., & Staels, B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.028 · Cited by 110
“Several reports suggest that the incretin effect is reduced in type 2 diabetic patients [21] [22], although recent studies indicate that the reduction of insulin secretion is primarily due to an impairment in β-cell function after chronic hyperglycaemia rather than a primary defect in glucose-dependent GLP-1 and GIP a…”
BackgroundIncretin hormone mimetics and analogues in diabetes therapeutics
Green, B. D., & Flatt, P. R. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.003 · Cited by 125
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
Ansar, S., Koska, J., & Reaven, P. D. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-61 · Cited by 112
“Notably, the incretin effect appears reduced or lost in individuals with impaired glucose tolerance and T2DM [79,80].”
BackgroundPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 111
Glycemic Variability: Risk Factors, Assessment, and Control
Kovatchev, B. P. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819826111 · Cited by 124
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Pratley, R. E., & Gilbert, M. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 111
“demonstrated that the incretin effect accounted for ~2/3 of the insulin secretory response in subjects with normal glucose tolerance, whereas in patients with T2DM it accounted for less than 20% (Figure 2) [16, 30].”
BackgroundThe pathogenesis of NIDDM involves a defective expression of the GIP receptor
Holst, J. J., Gromada, J., & Nauck, M. A. (1997) · Diabetologia · doi:10.1007/s001250050779 · Cited by 136
Self-citationLinagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
Kern, M., Klöting, N., Niessen, H. G., Thomas, L. H., Stiller, D., Mark, M., Klein, T., & Blüher, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038744 · Cited by 117
“The ‘incretin effect’ is significantly reduced in patients with type 2 diabetes mellitus (T2DM) and contributes to impaired insulin secretion and chronic hyperglycemia [6,7].”
BackgroundGhrelin Is a Novel Regulator of GLP-1 Secretion
Gagnon, J., Baggio, L. L., Drucker, D. J., & Brubaker, P. L. (2015) · Diabetes · doi:10.2337/db14-1176 · Cited by 111
The past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 109
Hansen, K. B., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0119 · Cited by 110
Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug
IDRIS, I. R., & Donnelly, R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00705.x · Cited by 124
Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., Peterson, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 108
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 109
“In type 2 diabetes, both direct glucose-induced insulin secretion (67,68) and incretin-mediated potentiation of insulin secretion are reduced (69).”
BackgroundDirksen, C., Hansen, D. L., Madsbad, S., Hvolris, L. E., Naver, L. S., Holst, J. J., & Worm, D. (2010) · Diabetes Care · doi:10.2337/dc09-1374 · Cited by 107
“Interestingly the insulin and C peptide response-curves found after gastroduodenal feeding resemble the responses found in type 2 diabetic patients, whereas the response-curves after peroral feeding are similar to those found in healthy control subjects (4).”
ResultEnteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery
Holst, J. J. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.014 · Cited by 116
Wouters, E. F. M., Bredenbröker, D., Teichmann, P., Brose, M., Rabe, K. F., Fabbri, L. M., & Göke, B. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2886 · Cited by 107
“DM2 is characterized by a severely reduced or absent incretin effect (6).”
BackgroundTargeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Gestational Diabetes Mellitus and Cardiovascular Risk after Pregnancy
Harreiter, J., Dovjak, G., & Kautzky-Willer, A. (2014) · Women's Health · doi:10.2217/whe.13.69 · Cited by 106
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
Therapeutic potential for GIP receptor agonists and antagonists
Irwin, N., & Flatt, P. R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.001 · Cited by 114
The Incretin Approach for Diabetes Treatment
Holst, J. J., & Ørskov, C. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s197 · Cited by 106
“(21) and has been probed in immunoneutralization studies (22) and, more recently, in studies employing a fragment, GIP (7-30)amide, which turns out to be a GIP receptor antagonist (23).”
BackgroundInfluentialType 2 diabetes mellitus—Its global prevalence and therapeutic strategies
Jain, S., & Saraf, S. (2008) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2008.04.011 · Cited by 124
The [pre-] history of the incretin concept
Creutzfeldt, W. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.004 · Cited by 123
Self-citationEmerging pharmacotherapies for obesity: A systematic review
Kokkorakis, M., Chakhtoura, M., Rhayem, C., Al Rifai, J., Ghezzawi, M., Valenzuela-Vallejo, L., & Mantzoros, C. S. (2025) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001045 · Cited by 102
Mechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes
Muscelli, E., Casolaro, A., Gastaldelli, A., Mari, A., Seghieri, G., Astiarraga, B., Chen, Y., Alba, M., Holst, J., & Ferrannini, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1205 · Cited by 104
“The incretin effect was operationally defined as the ratio of oral to iv (O/IV) for all insulin secretion measures (4).”
BackgroundZarrinpar, A., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12084 · Cited by 103
“Emerging data suggest that hepatic insulin resistance and hepatic steatosis precede the development of T2DM.105, 106 Elevated serum alanine aminotransferase and fatty liver on ultrasound predict the occurrence of diabetes.106, 107 A low-calorie diet is the primary therapy for insulin resistance and hepatic steatosis.”
BackgroundInfluentialTran, K., Park, Y. I., Pandya, S., Muliyil, N. J., Jensen, B. D., Huynh, K., & Nguyen, Q. P. H. (2017) · PubMed Central · Cited by 126
Mingrone, G., Nolfe, G., Gissey, G. C., Iaconelli, A., Leccesi, L., Guidone, C., Nanni, G., & Holst, J. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1288-9 · Cited by 111
“[3], that the beta cell incompetence observed in diabetes is, at least partially, due to an impaired effect of incretin.”
BackgroundGLP-1 based therapy for type 2 diabetes
Arulmozhi, D. K., & Portha, B. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.003 · Cited by 115
Shah, P., Ardestani, A. D., Dharmadhikari, G., Laue, S., Schumann, D., Kerr-Conte, J. A., Pattou, F. N., Klein, T., & Maedler, K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1029 · Cited by 108
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?
Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2003) · Neuropeptides · doi:10.1016/j.npep.2003.09.002 · Cited by 107
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99
“Twenty-seven years after the first publication by Nauck in Diabetologia [17], our understanding of the role of incretins in the pathophysiology of”
BackgroundGlucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 113
Self-citationThe Alliance of Mesenchymal Stem Cells, Bone, and Diabetes
Napoli, N., Strollo, R., Paladini, A., Briganti, S., Pozzilli, P., & Epstein, S. (2014) · International Journal of Endocrinology · doi:10.1155/2014/690783 · Cited by 110
“This pathway is attenuated in T2D [218] and the therapeutic target of drugs commonly used in T2D such as GLP-1 receptor analogues, which are resistant to DPP-4 degradation, and inhibitors of DPP-4, which extend the half-life or the native incretins [219].”
BackgroundPost-prandial hyperglycemia. post-prandial hyperglycemia and diabetes.
Gin, H., & Rigalleau, V. (2000) · PubMed · Cited by 135
Metadata
- Authors
- Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W.
- ORCID
- Nauck, M.
- Venue
- Diabetologia
- Published
- 1986-01
- Volume
- 29
- Issue
- 1
- Pages
- 46-52
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2054564814
- Cited by
- 1,307
- References
- 40
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 45 · 2023: 38 · 2022: 53 · 2021: 46 · 2020: 44 · 2019: 60 · 2018: 41 · 2017: 47 · 2016: 65 · 2015: 63 · 2014: 82 · 2013: 86 · 2012: 74
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, insulin secretion, C-peptide, glucose-dependent insulinotropic polypeptide, oral glucose tolerance, intravenous glucose infusion, hepatic insulin extraction, immunoreactive insulin
- MeSH terms
- Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Humans, Infusions, Parenteral, Insulin, Male, Middle Aged, Pancreas
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.